1Nguyen S, Kennedy M, Gunawardana D,et al. Safety and pharmaco- kinetics of acicIovir in women following release from a silicone elasto- mer vaginal ring. The Journal of Antimicrobial Chemotherapy,2012, 67 (8) : 2005 -2012.
2David I, Bernstein Rhonda D, Cardin Feruando J, et al. Topical SMIP - 7.7, a toll - like receptor 7 agonist, protects against genital herpes simplex virus type - 2 disease in the guinea pig model of geni- tal herpes. A ntiviral Chemistry & Chemotherapy ,2014,23 (5):189 - 196.
3Laura Shepherd. Common themes and cognitive biases in the negative thoughts of women with recurrent genital herpes: clinical reflections and implications for cognitive behaviour therapy. Sexual and Relation- ship Therapy, 2010,25 (2) :148 -159.
4Sita Awasthi, Jialing Huang, Carolyn Shaw,et al. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to en- hance efficacy of a trivalent subunit antigen vaccine for genital her- pes. J Virol,2014,88(15) : 8421 -8432.
5Nicolas ~uburu, Kening Wang, Kyle N Goodman,et al. Topical her- pes simplex virus 2 ( HSV - 2 ) vaccination with human papillomavir- us vectors expressing gB/gD ectodomains induces genital - tissue - resident memory CD8 + T ceils and reduces genital disease and viral shedding afler HSV -2 challenge. J Virol,2015, 89( 1 ) : 83 -96.
6Briana Nixon, Martha Stefanidou, Pedro MM Mesquita,et al. Grif- fithsin protects mice from genital herpes by preventing cell - to - cell spread. J Virol, 2013,87 ( 11 ) : 6257 - 6269.
7Awasthi John W, Balliet Jessica A, Flynn John M, et al. Protection provided by a herpes simplex virus 2 ( HSV - 2) glycoprotein C and D subunit antigen vaccine against genital HSV -2 infection in HSV - 1 -seropositive guinea pigs. Journal of Virology,2014,88 (4) : 2000 - 2010.
